|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LETTER |
Susan J. Klein, Daniel A. OConnell, and Alma R. Candelas are with the New York State Department of Health (NYSDOH) AIDS Institute, Albany, NY. James G. Giglio is with the NYSDOH Bureau of Narcotic Enforcement, Albany. Guthrie S. Birkhead is with the NYSDOH AIDS Institute, the NYSDOH Center for Community Health, and the School of Public Health, University at Albany, Albany.
Correspondence: Requests for reprints should be sent to Susan J. Klein, NYSDOH AIDS Institute, Corning Tower Room 412, Albany, NY 12237-0658 (e-mail: sjk06@health.state.ny.us).
|
|||
Drug overdose is a public health concern, and the opioid class of drugs is a significant cause of overdose-related fatalities.1,2 Hundreds of deaths associated with fentanyl-laced heroin and findings that 19% of US adolescents have taken prescription pain killers to get high underscore the need for attention.3,4 New York State, a large jurisdiction, has recognized the need to respond.
As noted by Paulozzi, regulating and monitoring controlled substances is important for an effective public health response.1 One of New York States most important tools in preventing prescription drug abuse is the Official Prescription Program, a prescription monitoring program that has
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |